button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 ---
versus placebo
durvalumab alone vs. placebo 1 ---
pembrolizumab alone vs. placebo 1 ---
versus placebo plus SoC
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo plus SoC 1 certainty unassessable-29%--

es-BC - TNBC - NA - PDL1 positive breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - PDL1 positive

versus placebo plus SoC
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo plus SoC 1 ---

mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1)

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-10% certainty unassessable-17%-
versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable-13% certainty unassessablestatistically conclusive-18%-
atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable+12% certainty unassessable-13%-

mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 2 statistically conclusive-17%statistically conclusive-26%-
versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable-27% certainty unassessablestatistically conclusive-35%-
atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable+11% certainty unassessable-17%-

mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)

mBC - TNBC - L2 - all population breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - all population

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessable-3% certainty unassessable+60%-

mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 2 certainty unassessable-13% certainty unassessable+35%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons